Pardoll D M
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Immunol Today. 1993 Jun;14(6):310-6. doi: 10.1016/0167-5699(93)90051-L.
1993 represents the 100th anniversary of William Coley's first report of tumor regressions induced by immune system activation in response to bacterial toxins. While many subsequent cancer vaccine trials have yielded tantalizing results, active immunotherapy has not yet become an established modality of cancer therapy. Newer molecular vaccine approaches based on rational immunological principles have resulted in improved systemic antitumor effects in animal models. Ultimately the genetic definition of tumor-specific antigens will allow the development of targeted antigen-specific vaccines for cancer therapy.
1993年是威廉·科利首次报告免疫系统因细菌毒素激活而导致肿瘤消退的100周年。虽然随后的许多癌症疫苗试验都取得了诱人的成果，但主动免疫疗法尚未成为一种成熟的癌症治疗方式。基于合理免疫学原理的新型分子疫苗方法已在动物模型中产生了更好的全身抗肿瘤效果。最终，肿瘤特异性抗原的基因定义将有助于开发用于癌症治疗的靶向抗原特异性疫苗。
